KURA
Companies
NASDAQ
Kura Oncology Inc.
Health Care
$6.06
-$2.65 (-30.42%)
Price Chart
Overview
About KURA
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Market Cap
$1.7B
Volume
6.6M
Avg. Volume
8.6M
P/E Ratio
-2.389513
Dividend Yield
0.00%
Employees
144.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.38
High Correlation
Volatility
High (0.64)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, KURA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.7B
Volume6.6M
P/E Ratio-2.39
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 2, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025